Method for detecting human papillomavirus mrna
First Claim
1. An in vitro method of screening human subjects to assess their risk of developing cervical carcinoma, which method comprises screening the subject for expression of mRNA transcripts of the E6 gene of HPV and sorting the subject into one of two categories of risk for development of cervical carcinoma based on expression of E6 mRNA, wherein individuals positive for expression of E6 mRNA are scored as carrying integrated HPV or a modified episomal HPV genome and are therefore classified as high risk for development of cervical carcinoma, whereas individuals negative for expression of E6 mRNA are scored as not carrying integrated HPV or a modified episomal HPV genome and are therefore classified as no detectable risk for development of cervical carcinoma, characterised in that screening for E6 mRNA expression is carried out using isothermal amplification in combination with real-time detection of the amplification product.
1 Assignment
0 Petitions
Accused Products
Abstract
An in vitro method is provided for screening human female subjects to assess their risk of developing cervical carcinoma which comprises screening the subject for expression of mRNA transcripts from the E6 and optionally the L1 gene of human papillomavirus, wherein subjects positive for expression of L1 and/or E6 mRNA are scored as being at risk of developing cervical carcinoma. Kits for carrying out such methods are also provided.
52 Citations
19 Claims
- 1. An in vitro method of screening human subjects to assess their risk of developing cervical carcinoma, which method comprises screening the subject for expression of mRNA transcripts of the E6 gene of HPV and sorting the subject into one of two categories of risk for development of cervical carcinoma based on expression of E6 mRNA, wherein individuals positive for expression of E6 mRNA are scored as carrying integrated HPV or a modified episomal HPV genome and are therefore classified as high risk for development of cervical carcinoma, whereas individuals negative for expression of E6 mRNA are scored as not carrying integrated HPV or a modified episomal HPV genome and are therefore classified as no detectable risk for development of cervical carcinoma, characterised in that screening for E6 mRNA expression is carried out using isothermal amplification in combination with real-time detection of the amplification product.
- 2. An in vitro method of identifying human subjects having abnormal cell changes in the cervix, which method comprises screening the subject for expression of mRNA transcripts of the E6 gene of HPV, wherein individuals positive for expression of E6 mRNA are identified as having abnormal cell changes in the cervix, characterised in that screening for E6 mRNA expression is carried out using isothermal amplification in combination with real-time detection of the amplification product.
- 10. A kit for use in the detection of mRNA transcripts of the E6 gene(s) of HPV, the kit comprising one or more primer-pairs which enable amplification of a region of E6 transcripts from HPV types 16, 18, 31 and 33 by NASBA and one or more molecular beacon probes.
Specification